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In this supplement to the Journal of the American College of
Cardiology, we are treated to a superb recount of the history,
birth, growth and development of coronary revascularization
as it exists today in the form of coronary artery bypass graft
surgery (CABG) and percutaneous transluminal coronary an-
gioplasty (PTCA). Rare is the cardiovascular specialist of
today who at one time or another during his or her professional
life has not been involved in either the diagnosis, management
or disposition of a patient who has undergone myocardial
revascularization. Presenting this historical perspective are
Rene G. Favaloro and Spencer B. King III.
The Surgeon
Who better to tell the story of CABG than Favaloro,
universally acclaimed as the father of the procedure based on
work he began during his training years at the Cleveland Clinic.
This Argentinean surgeon systematically perfected a surgical
technique, rather common in its day among peripheral vascular
surgeons, of using saphenous vein segments to bypass arterial
obstructions and demonstrated that this could be done success-
fully and safely for the management of obstructed epicardial
coronary arteries by means of cardiopulmonary bypass. His
first-person account of the decade of discovery that began for
him in February 1962 gives ample testimony to the fact that
this particular breakthrough in cardiac surgery would not have
occurred were it not for the combined efforts and contributions
of a team comprising a clinical cardiologist (William Proudfit,
MD), a catheterization laboratory director (F. Mason Sones,
MD) and a pioneer surgeon (Donald B. Effler, MD). His
stories of confronting the early skeptics and many academics
who questioned the merits of CABG are not only quite true
but are told with the same Latin passion and conviction that
many of us witnessed at the various heart meetings in the
mid-1960s, when this topic dominated the program. You could
virtually palpate his frustration when he would present reason-
able data to support his contention that this form of revascu-
larization immediately brought new blood flow to the ischemic
myocardium, restored local perfusion, improved myocardial
performance and relieved symptoms . . . and it was questioned.
Not withstanding, few physicians or surgeons have ever seen
their original ideas and early contributions so clearly supported
by the accumulation of data over time as has Favaloro.
However, this is not what has sustained the man. As we read
further on in his piece, what he has to say about CABG in the
1980s, about PTCA and the randomized comparisons with
CABG (completed only in the middle of this decade), about
CABG in the thrombolytic era and its role in acute myocardial
infarction as well as in the asymptomatic patient, shows a
scholar at work. His insights into these contemporary issues are
sometimes profound, sometimes surprising but always based
on a careful reading and a scholarly analysis of the published
reports. Quite clearly he has an intimate and working knowl-
edge of each of the 1,065 references that he cites in his
presentation here. This fact alone makes the reading of
Favaloro’s “Critical Analysis of Coronary Artery Bypass Graft-
ing: A 30-Year Journey” (1) a worthwhile read, even for the
present-day clinician who maybe unlucky enough to have little
to no interest in the history of medicine.
The Interventionalist
Equally appropriate is the selection of Spencer B. King III
to write the matching piece on the development of interven-
tional cardiology (2). Although there are many individuals of
acknowledged achievement who had intimate association with
Andreas Gruentzig, the founding father of PTCA, in the
beginning days of coronary angioplasty, no one had more
influence or equal success in recruiting Gruentzig to this
country and to his own institution.
As he states in the early and quite intriguing pages of his
story, King was aware of Gruentzig’s dissatisfaction with the
constraints placed on him in developing the technique of
angioplasty in Zurich, but he also knew that as much as
Gruentzig wanted the proper environment in which to devote
full time to the further development of the technique, he also
wanted an academic professorship. In response to King’s
invitation in 1980, Andreas Gruentzig called him from Snow-
mass, Colorado, where he was participating in Vogel’s Amer-
ican College of Cardiology (ACC) course to say he would drop
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by on his way home to Zurich. After some intense meetings at
Emory University, it appeared that Willis Hurst could most
likely be effective in securing the professorship, but there
would certainly be visa problems for a foreign-born and
foreign-trained physician to immigrate permanently to Geor-
gia in the 1980 era. At a hastily arranged luncheon with the
powers of academe at Emory University scheduled to meet
Gruentzig at the notoriously stodgy Piedmont Driving Club,
King noticed Griffin Bell, the Attorney General under Presi-
dent Carter, at the next table. With the instincts of an eagle
scout, King went over to the Attorney General’s table, greeted
the man he knew only peripherally and promptly introduced
him to Andreas Gruentzig. This chance encounter lasted just
long enough for two southern gentlemen to identify a strategy
that most likely would prove successful in meeting the require-
ments for legal immigration to this country. Add this anecdote
to the others so warmly told in his editorial, “Angioplasty from
Bench to Bedside to Bench” (3), and you have a picture of “the
life and times of Andreas Gruentzig,” as told by Spencer King.
More important, to clinch the recruitment in 1980, King had
given over the organizational structure, facilities and resources
already in place at Emory to mount his own assault on this
promising new field.
In Spencer King, Gruentzig found not only a talented and
technically skillful operator but also a compleat cardiologist who
knew far more about caring for the sick cardiac patient than his
own limited training had equipped him for. His new American
associate also knew cardiac physiology; understood the bene-
fits, risks and limitations of cardiac surgery; and was, in his own
right, highly regarded by the cardiology establishment in this
country. It was as much these qualities and the comportment of
his friend and contemporary that would modulate the passion-
ate drive of this charismatic but oftentimes impatient investi-
gator as it was Gruentzig’s own genius that made for the
success that was to make Atlanta, Georgia, the new epicenter
for the advancement of angioplasty in the early 1980s.
In rapid fashion the field witnessed the establishment of an
angioplasty registry to which all operators in North America
would subscribe or have balloon catheter deliveries restricted;
the move toward multivessel angioplasty and the use of the
procedure in acute myocardial infarction; the development of
over the wire catheter systems; and, most important, the
development of steerable guide wires that dramatically im-
proved the ability to reach distal segments of the coronary tree.
Before Gruentzig’s untimely death in a 1985 plane crash, he
and his collaborators had laid out plans for a randomized trial
comparing PTCA with CABG at Emory. They also experi-
mented with new devices, such as rotablaters, lasers and even
stents, that were to see their formal development later in the
decade.
On examining the legacy left by Andreas Gruentzig, we find
that it was Spencer King who completed the 10 year follow-up
of the 169 patients who underwent angioplasty by Gruentzig in
Zurich between 1977 and 1980. In collaboration with Maria
Schlumpf, Gruentzig’s long-time assistant, he reported a 90%
survival rate for those whose initial procedure was successful
and that only 23% of these patients underwent bypass surgery
for these or progressive lesions elsewhere during the 10-year
period of follow-up (4). Earlier, King had reported on the
5-year follow-up of a consecutive series of .400 patients who
underwent PTCA at Emory after Gruentzig’s arrival (5). By
1987, King had an RO1 grant from the National Heart, Lung,
and Blood Institute (NHLBI) to carry out a single-center,
randomized trial comparing PTCA with CABG. The Emory
Angioplasty Versus Surgery Trial (EAST) was carried out in
keeping with the original design by Gruentzig and reported its
findings in The New England Journal of Medicine in 1994 (6).
I have elaborated in some detail on the two authors who
have written these historical pieces for the benefit of those who
have not lived this history—and your number is sizable.
According to the ACC, the median age of the 21,455 American
cardiovascular specialists listed in its membership file is 47
years. This would suggest that more than half of the Journal’s
readership was only 8 years old when Mason Sones performed
selective coronary angiography for the first time; ;18 years old
when Favaloro performed his first saphenous vein bypass graft
(7); and less than half the membership had completed their
training when Gruentzig reported his four cases of successful
PTCA at the Scientific Sessions of the American Heart Asso-
ciation in 1977.
The message is not so much: “ergo, read this rich history” as
it is to be cognizant of those who wrote it. Both Favaloro and
King are very much in the mainstream of present-day cardiol-
ogy. Favaloro maintains the same body-breaking operating
schedule in his institute in Argentina today as he did in the
1960s in Cleveland. King who, in my view, already serves as the
Dean of interventional cardiology in this country, is about to
serve as the next President of the ACC. As such, they both
could be mistaken for present-day leaders merely chronicling
the events of the past. Quite to the contrary, they are the
original architects who laid the foundations for what many
within the cardiology community consider to be its most
important achievement of the century. What they have to say
about the subject they know so well is deserving of careful
reading by all who would care for a cardiac patient in modern
times.
The Clinician
As someone who by dint of birth and the abundant good
fortune to be a cardiology fellow in the catheterization labo-
ratory of Walter Abelmann at the Thorndike Memorial Lab-
oratories of Boston City Hospital and Harvard Medical School
just as the angiographic work of F. Mason Sones was being
recognized, and was on the scene as an aspiring young cardi-
ologist in these times, I offer a few observations to bear witness
to the impact of the dawn of coronary revascularization. Like
Favaloro and King, I, too, view Sone’s achievement of selective
coronary arteriography as the seminal event that prepared the
way for the development of coronary revascularization. Figure
1 shows a cine frame taken from the first selective coronary
arteriogram recorded by Sones on October 30, 1958. This was
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exactly 2 days after the “inadvertently obtained” selective
coronary cineangiogram that took place in his catheterization
laboratory when an aortic root injection whiplashed the cath-
eter into the ostia of the right coronary artery, as described in
“Background for Angioplasty” in King’s presentation. Louis
Pasteur must have had the likes of Sones in mind when he
uttered his celebrated aphorism, “in the fields of observations,
chance favors only the prepared mind.” No longer concerned
that disrupting the coronary circulation with a bolus of dye
would cause a lethal electrical imbalance and produce a fatal
arrhythmia, as had been predicted by the electrocardio-
graphers of the day, Sones demonstrated that by coupling
sophisticated X-ray equipment with high quality recording cine
cameras, diagnostic angiographic images of the coronary ar-
teries could be obtained. The image in Figure 1, although fuzzy
by today’s standards, was truly an achievement of monumental
proportions when it was recorded 40 years ago. Figure 2 is an
improved cine frame image taken by Sones 9 years later. It is
a cine frame of the first aortocoronary saphenous vein graft
inserted by Rene Favaloro in May 1967. I am indebted to
Dellos M. Cosgrove III who presented these images to me .15
years ago.
My earliest interaction with Sones took place in the winter
of 1960 when he came to Boston to deliver a Boston City
Hospital House Officers lecture. At the time I was a first-year
fellow totally immersed in the problem of recording accurate
cardiac output by indicator dilution using the Hamilton for-
mula. It thus seemed logical after Sones had dazzled us all with
marvelous cineangiograms and cineventriculograms projected
on 35-mm film to ask him what technique he used to measure
cardiac output in these cases. I clearly remember the words of
his answer: “Son, if you have to wonder about cardiac output
measurements when you can see ventricles squeeze like I have
just shown you, you have no imagination at all.” His stature
and delivery reminded me very much of the actor James
Cagney, who gained fame by portraying the song and dance
man, George M. Cohan, as well as scrappy little gangsters.
Be that as it may, I carried away from this very early
demonstration of cineangiography that Sones had given us the
first in vivo marker available for the diagnosis of coronary
artery disease. It also inspired me to equip the new catheter-
ization laboratory that I was to direct at St. Elizabeth’s
Hospital on the completion of my fellowship with the latest
X-ray equipment, featuring a pulsed generator using an exper-
imental grid control system to produce short-pulse exposures
of adequate energy for small focal-spot X-ray tubes to record
sharp images of coronary arteries. Joining this early cult of
coronary angiographers, I not only learned the art of hand
developing fine-grained cine film and the secrets of overfram-
ing on 16-mm film, but I quickly learned that in contrast to all
other diseases about which I knew something, the severity of
symptoms (usually angina) did not necessarily correlate with
the severity of disease. Not infrequently, a patient with severe,
unstable angina refractory to medical therapy would have only
single-vessel disease, whereas another patient with fewer clin-
ical complaints would be found to have extensive three-vessel
involvement. It also became apparent that patients with coro-
nary artery disease were much more fragile on the catheter-
ization table than were patients with valvular or congenital
heart disease whom we were accustomed to studying, often
with lengthy protocols. The patients with coronary artery
disease seemed to fatigue earlier, often developed angina
during the procedure and were more prone to develop hemo-
dynamic instability that seemed more difficult to control than
our other patients with heart disease. Surely this had some-
thing to do with their generally being older, but it was clear
these patients differed in many ways from the majority of
patients who were undergoing catheterization as a prelude to
open heart surgery for the correction of a valvular or congen-
ital lesion.
By the mid-1960s a sufficient number of patients had
undergone coronary arteriography and had been followed up
Figure 2. Cine frame taken by Sones of the first aortocoronary
saphenous vein graft inserted by Rene Favaloro in May 1967.
Figure 1. Cine frame from the first selective coronary arteriogram
taken by Mason Sones on October 30, 1958.
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for $5 years to allow some estimates of the natural history of
patients with the angiographic marker of coronary disease,
almost all of whom had severe symptoms. These studies
concluded that the annual mortality rates for patients with
coronary artery disease could be expressed according to the
simplistic yet Sones-established classification of one-, two- or
three-vessel disease. For patients with single-vessel disease, the
annual mortality rate was generally to 2% to 4%, for two-vessel
disease 7% to 8% and for three-vessel disease 12% (7,8).
It was also true that by the late 1960s, most cardiologists
were quite comfortable caring for patients after open heart
surgery performed for either acquired mitral or aortic valvular
disease or one of the major adult congenital heart lesions. The
operative mortality rate ranged from 4% to 8% for mitral valve
replacements and somewhat higher for aortic valve replace-
ment. With the exception of angiotensin-converting enzyme
(ACE) inhibitors, we had many of the same drugs available to
treat congestive heart failure, hypertension and arrhythmias as
we have today. By this time we were also aware of the newer
surgical techniques being used at the Cleveland Clinic and in
Canada to treat the patient with coronary artery disease. The
word from Cleveland was that direct atherectomy and other
cosmetic repairs of the atherosclerotic lesion itself were atten-
dant with a frightful mortality such that they would never be
accepted by the clinical community. The Vineberg operation,
which essentially consisted of burying the bleeding pedicle of
an internal mammary artery into a tunnel made in the cardiac
muscle without any direct anastomoses, appeared to hold the
most promise of any of the surgical techniques, primarily
because it could be done with an acceptable mortality. It was
based on the observations that implanting a pumping artery
into the myocardial syncitium did not result in the formation of
hematoma; rather, it opened nascent collateral channels and
fostered neovascularization that, over time, would enrich the
blood supply to ischemic myocardium.
The Vineberg procedure found enthusiastic support in
Boston by the late Richard Gorlin, who at the time was
conducting elegant metabolic studies in patients with coronary
artery disease. He and his surgical colleague at the Peter Bent
Brigham Hospital, Warren Taylor, reported on a large series of
patients undergoing internal mammary implantation, with a
surgical mortality rate of 5% (10). I was less enthusiastic about
the procedure because it took, on average, 3 months to develop
adequate collateralization, during which time the patient was
expected to survive the trauma of the surgical procedure and
continue on as a very symptomatic patients with heart disease
until the new blood supply functioned. Additionally, Sones was
able to demonstrate patent implants with opacification of the
native coronary arteries in only 69 (54%) of 127 patients
studied postoperatively after undergoing double internal mam-
mary implantation performed by Favaloro et al. (11).
Such was the clinical climate when Favaloro undertook an
organized approach to saphenous vein bypass grafting (7). Like
most major innovations in medicine, it arrived on the scene as
an evolutionary process. As both Favaloro and King point out,
the procedure had actually been performed as early as 1964 by
Garrett as an emergency attempt to save a patient who was
undergoing an endarterectomy, although this was not reported
until 1973 (12). It was also an operative technique used by
peripheral vascular surgeons that was very successful in restor-
ing limb blood flow, although such patients had a very high
incidence of perioperative myocardial infarction. Before the
learning curve of this procedure performed on the epicardial
coronary arteries was completed, it was widely recognized that
for patients who had received maximal drug therapy and yet
remained intolerably symptomatic, bypass surgery clearly
added a brilliant therapeutic advantage (13,14). It was
promptly demonstrated that this form of revascularization
immediately restored blood flow to the affected areas of the
myocardium and accounted for the improved symptoms, in-
creased exercise tolerance, improved myocardial performance
and was responsible for an improved quality of life. It is well to
recall that medical therapy at this time included the abundant
use of topical nitrates as well as some oral, long-acting nitrates
and the widespread use of the beta-adrenergic blocking agent
propranolol that had been reported on as early as 1964 by
Hammer et al. (15) from London. If one consults the third
edition (1966) of Charles K. Friedberg’s Diseases of the Heart,
arguably the leading cardiology textbook of its time, one
appreciates that the medical therapy of heart disease routinely
included the use of lasix, digitalis, spironolactone, propranolol,
procaineamide, quinidine, hydralazine and nitrates. In brief,
the clinical improvement after CABG compared with medical
therapy was as dramatic to the clinician as was the introduction
of penicillin for the treatment of pneumonia. Although
Favaloro was aware of the acceptance of his operation by the
practicing community, I believe that he was intellectually
distracted by the nay-sayers who demanded scientific proof by
randomized comparisons.
This at least was my sense from conversations that we had
on the first occasion that I met Favaloro in 1969. He had
accepted my invitation to present Grand Rounds at St. Eliza-
beth’s Hospital in the fall of that year. Although his fame had
far from crested, he was much in demand, and I was impressed
at how gracious and accommodating he was in accepting the
invitation of this unknown cardiologist to speak in a city with
far more prestigious institutions. His lecture was memorable,
and his results bordered on the spectacular: The operative
mortality rate in this very early series was 4.2% (1). During that
visit, we conversed and interacted much as two chief residents
might have discussed a case rather than as a host with a guest
star. I was struck that he was not only a man with great vision
but also a man with a common touch. As I was to learn a few
years later, it was precisely these qualities that inspired him as
a younger man to write a definitive history of his country and,
reciprocally, inspired his countrymen to attempt to draft him
for President of Argentina in the stormy, post-Peron days.
The remainder of the CABG story is far better told in the
words of Favaloro himself, and it needs no further embellish-
ment from this source. However, there are three points that I
believe are worth making regarding bypass surgery in the
1970s: 1) By 1974 the in-hospital mortality rate for CABG by
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the Cleveland Group was 1.4%, postoperative myocardial
infarction 4.1% and graft patency 83.6% (1). These are envi-
able statistics even today. 2) The NHLBI-funded Coronary
Artery Surgery Study (CASS) had two separate and distinct
components: a) the CASS randomized trial, and b) the CASS
registry (16). The former was limited to 780 patients who were
successfully entered into a randomized comparison of medical
therapy versus bypass surgery with the aim of answering the
somewhat broad public health issue raised by the success of
CABG in severely symptomatic patients. The question was, If
the operation is so successful in patients with severe symptoms,
would not the improved blood flow be helpful and prolong
survival even in those patients who are minimally or totally
asymptomatic but who had coronary artery disease? (17). It
was not the same as the earlier Veterans Administration
Cooperative Study (18) or the European Coronary Surgery
Study (ECSS) (19), which were more directed to comparing
sicker patients who often underwent coronary bypass surgery.
For them the question was more, Which is truly better—
medical therapy or operation—when you test by random
assignment? The CASS registry is a large databank developed
by the CASS Investigators who agreed to record baseline and
follow-up data for every consenting patient undergoing coro-
nary arteriography for known or suspected coronary disease
during recruitment of patients for the randomized trial. In fact,
24,959 patients comprised the registry and included patients
without angiographically demonstrable coronary disease as
well as patients with severe, unstable angina and cardiogenic
shock. It was both the size and heterogeneity of the registry
population that made it such a uniquely valuable repository
from which to study the full spectrum of coronary disease.
More than 150 publications eminated from this databank and
addressed a wide variety of questions that could only be posed
in a very large, well characterized population for whom reliable
long-term follow-up information was available (all patients
entered into the registry were followed up on an annual basis
for a minimum of 5 years). With the exception of 11 publica-
tions relating to the randomized cohort, all publications from
the registry rely on observational data (16). In contrast, the
CASS randomized trial asked a sharply focused question
targeted to a clearly defined population (i.e., those with very
mild or no symptoms of angina). There were actually 2,099
patients who met the inclusion/exclusion criteria for the ran-
domized trial, but only 780 patients consented to randomiza-
tion (37.2% of the true study population). This point was
missed by a number of critics of the trial when it was initially
published, and they argued that the randomized trial had little
relevance because the 780 randomized patients represented
only 4.7% of the 16,595 patients with coronary artery disease
who underwent arteriography at the participating institutions
during the time frame of the study (20). Part of the genius of
the CASS study design was the decision to provide clear and
thorough follow-up of the 1,319 patients who, although quali-
fied for randomization, chose not to be randomized (21).
Referred to as “randomizable” patients, they received either
medical treatment or underwent coronary bypass surgery on
the basis of the recommendations of their treating physicians
and were not part of the randomized assignment. The survival
curves of the medically treated randomizable patients were
superimposable on the medically assigned randomized survival
curves in all analyses that were performed. Similarly, survival
curves of the randomizable patients who underwent bypass
surgery were superimposable on the survival curves of the
surgically assigned randomized patients. This includes the
crossover rates from medical therapy to bypass surgery being
identical between the randomized and randomizable medical
patients (21).
Considering the fact that approximately one-half of the
cardiologists practicing today entered practice since the publi-
cation of the CASS trial, it is perhaps worthwhile to recall the
admonition of the philosopher Santayana: “Those who do not
learn from history are doomed to repeat it.” Since both
medical and surgical therapies of overt coronary artery disease
still remain palliative, and neither is curative, there are still
lessons to be learned from the CASS registry studies, many of
which are not likely to be repeated. There are three registry
studies that I consider seminal. One relates to the survival of
medically treated patients in the CASS registry that contrasts
the natural history of patients with coronary artery disease in
the mid-1970s with the earlier natural history of the 1960s. The
cumulative 4-year survival of medically managed patients was
analyzed among 20,088 patients who were enrolled in the
registry without previous CABG (22). For the 5,804 patients
who did not have significant obstructing coronary lesions at the
time of angiography, the 4-year survival rate was 97% in
contrast to 92%, 84% and 68% in equally large patient groups
with one-, two- and three vessel disease, respectively. There
were 2,033 patients in this analysis who had three-vessel
disease and normal left ventricular function. They were shown
to have an annual mortality rate of 4.5%, in contrast to an
annual 8% mortality rate for the 785 patients with three-vessel
disease and impaired ventricular function, defined as left
ventricular ejection fraction (LVEF) ,0.50 but .0.35. For
patients with an LVEF ,0.35 and three-vessel disease, the
annual mortality rate was 12%/year. Although these results
showed a better cumulative survival of medically treated
patients with one-, two- and three-vessel disease than reported
a decade earlier, it was underscored that left ventricular
function had an important influence on subsequent survival
independent of the number of vessels diseased.
The second critically important study relates to patients
.65 years old, who were excluded by study design from the
randomized trial. The results of CABG were compared with
those of medical therapy alone in 1,491 nonrandomized pa-
tients $65 old (23). The cumulative survival rate at 6 years,
adjusted for major differences in important baseline character-
istics, was 79% in the surgical group and 64% in the medical
group (p , 0.0001). At 5 years, chest pain was absent in 62%
of the surgical group and 29% of the medical group (p ,
0.001). Analysis of this cohort by the Cox proportional hazards
model suggested an independent beneficial effect of CABG on
survival (p , 0.0001). The third publication from the CASS
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registry that I consider seminal is that by Ringqvist et al. (24)
demonstrating that in addition to the number of vessels
diseased, the location of an obstruction within the coronary
vessel and the state of the heart muscle best predict the
outcome of patients with coronary artery disease over a 6-year
follow-up period. Favaloro has also singled out this publication
as verifying his long-held opinion that the single-, double- and
triple-vessel disease classification is inadequate for the proper
analysis of patients with coronary artery disease, particularly if
we wish to compare different populations undergoing different
treatments. He summarizes the essential findings of this study
in Table 16 of his presentation, and I completely share his view.
It is clear from Favaloro’s presentation that he has been a
stern yet constructive critic of the CASS randomized trial from
its initial report in 1983. Although I sympathize with his angst
at the way that the lay press “missed the point” of this
particular subset of mildly symptomatic patients and incor-
rectly extended its headline coverage to include all patients
undergoing CABG, there are some basic points on which he
and I fundamentally disagree. Among these I include the
scientific analysis and conclusions drawn from the randomized
and randomizable patients; also the need to present the
primary analysis of a randomized trial by the “intention to treat
method” as the only valid way to maintain the scientific
integrity of the randomization process. Patients must be al-
lowed to “cross over,” but the robustness of one’s conclusion
will be weakened by the degree to which they do this. In this
regard I point to the original presentation of the survival data
of the randomized trial (17) in which the investigators indi-
cated that the data were also analyzed by “treatment received”
and did not alter the findings.
With the passage of time, there are many more things on
which Favaloro and I agree than disagree. For example, he was
the first to point out to me in a personal communication that
the definition of left anterior descending coronary artery
(LAD) disease as defined in CASS as a stenosis present in
segments 12, 13, 14, 15 or 16 in its widely used coronary
anatomy diagram differed substantially from all other conven-
tional definitions of LAD disease. This was so because it
included lesions both above and below the first septal perfo-
rator and lesions in the midportion and in the first and second
diagonal branches as well. Learning this, I could now under-
stand why the Duke databank differed from the CASS registry
databank on only one point, that is, the natural history of
single-vessel disease was the same for all three vessels (right,
LAD and circumflex vessels) in CASS, whereas the Duke data
showed a higher mortality rate for LAD disease than for single
lesions in the right or circumflex vessels. The CASS diagram
was created during the design phase of the study in 1974 and
underscores the importance of the independent angiographic
indexes reported by Ringqvist et al. (24) a decade later.
Although it took 10 years of enthusiastic participation as a
Principal Investigator in the CASS study for me to fully
understand the biostatistics that Favaloro then covered so well
in less than a full page of his present paper, most of us emerged
from the CASS experience with a high regard for the rigorous
science associated with the proper conduct of a randomized
trial. However, I do not view any of us as idol-worshipers
before the altar of randomized trials. To the contrary, my
exposure to the CASS registry databank gave me a keen
appreciation of the power of observational data—so much so
that I must admit that my current view of the relative merits of
surgical versus medical therapy for patients with coronary
disease is best summarized in a 15-year perspective on the
evolution of medical and surgical therapy for coronary artery
disease derived from the Duke database and presented by
Califf et al. (25). In the presentation by Favaloro, Figure 4
summarizes the data from that report, which compares medical
and surgical hazard ratios for patients treated in 1970, 1977
and 1984 and shows a progressive shift to the left during these
time frames, indicating an increasing benefit for surgical
therapy according to coronary anatomy. Basically, from 1990
onward my dictum has been: the sicker the patient clinically
and angiographically and the poorer the heart function, the
greater my enthusiasm for surgical therapy.
This same type of analysis was extended by Jones et al. (26)
to include 6,814 patients undergoing CABG or PTCA at Duke
between 1980 and 1990. This seminal report on how to
compare patients with coronary artery disease receiving differ-
ent therapies uses nine coronary anatomy groups similar to the
anatomic indexes used by Ringqvist et al. (24). Figures 8 and 9
in Favaloro’s presentation display the data from their report.
Figure 8 shows the point estimates of the adjusted hazard
ratios comparing CABG and medical therapy for the nine
coronary anatomy groups, and Figure 9 shows the comparison
between CABG and PTCA for the same anatomy groups. It
would appear that Favaloro, King and I all agree that this
method of analysis captures the “real world” of revasculariza-
tion therapy and does not suffer from the constraints of a very
selected population imposed by randomized, controlled trials.
Any question that I may have had regarding the validity of
this type of observational data analysis has been settled
permanently by data that are soon to be published from the
New York State database involving the PTCA and CABG
experience of 59,576 patients between the years 1993 and 1995.
The point estimates, along with their 95% confidence intervals,
for the adjusted hazard ratios comparing CABG and PTCA for
eight comparable coronary anatomy groups are virtually super-
imposable on the hazard ratios derived from the Duke data-
bank 10 years earlier (Hannan E, personal communication,
January, 1998). The weight of this type of validation of the
original method of Jones et al. (26) for comparing the two
procedural methods of achieving coronary revascularization is
bound to have a profound influence on the the design and
objectives of future randomized trials that involve major
interventional procedures. I believe they will have strict entry
criteria restricting the study population to a well defined subset
to answer a narrowly focused question.
The advent of multivessel angioplasty did much to change
the nature of patients undergoing CABG. As Edwards et al.
(27) have pointed out, the database of the Society of the
Thoracic Surgeons has shown a steady increase in baseline risk
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factors among the patients operated on between 1980 and
1990. Age has increased on average from 58.5 to 64.1 years,
and there has been a trend toward a higher proportion of
women (17% vs. 27%), a progressively lower LVEF (from 62%
to 51%) as well as the number of emergency and urgent
operations (from 4.1 to 8.2%) during the decade. Table 1
shows the difference in six major risk variables for coronary
revascularization comparing 29,646 patients undergoing
CABG with 29,930 patients undergoing PTCA in New York
State between 1993 and 1996 (Hannan E, personal communi-
cation, January, 1998). The magnitude and significance of the
differences between the two treatment groups make it highly
unlikely that anything other than a specially selected subgroup
of patients will qualify for randomized comparisons between
the two treatments.
To this seasoned (older) clinician, the era of PTCA repre-
sents modern times, and my personal involvement in its growth
and development has been mostly as an interested observer
and never as an operator. I do take pride in the fact that some
of the earliest work on the mechanism by which transluminal
angioplasty increases lumen diameter was done in our labora-
tories at Boston University Medical Center. My colleagues
David Faxon and Timothy Sanborn published seminal work
indicating that intimal fracture, dissection or thinning of the
nonatherosclerotic portion of the vessel wall and local aneu-
rysmal formation was the responsible mechanism, with no
evidence of compression, remodeling or embolization of the
atheromatous material (28–30).
Chairing the two ACC/AHA committees that published
guidelines for PTCA in 1988 and again in 1993 was a unique
learning experience and provided interesting insights into the
world of endovascular revascularization. I witnessed the cre-
ation of type A, B and C angiographic lesions by the consensus
opinion of some extremely talented interventionalists who
drew on their own personal experience to formulate the
classification that is not only in use today but has had its
predictive value for success rates and complications repeatedly
validated in the published experience (31). The same can be
said about the consensus opinion of a knowledgeable commit-
tee arriving at a minimum volume to maintain competency in
the performance of angioplasty. The number—75 cases/year—
for the maintenance of competence emerged as a battle cry for
revolt. It has been viewed as an example of arbitrariness in the
extreme, totally unsupported by data. It was most interesting to
see in the reports published in 1997 three major publications
reporting on an experience with .172,000 angioplasty proce-
dures that correlate outcome with individual physician experi-
ence in very large databases enrolling tens of thousands of
patients carefully characterized to allow adjustment for base-
line and procedural risks. The median number to emerge from
these studies was, coincidentally, 75 cases/year (32–34).
I also drew from this experience of writing guidelines an
appreciation of just how critical it is for the interventional
community at large to be aware of the new ground on which
they tread regarding moral and ethical issues. Issues that were
once abstract concepts for the physician now have a new and
heightened sense of reality, such as the issues of self-referral,
secondary gain, relations with industry, totally informed con-
sent, and dual obligations to the patient and to society regard-
ing the use of expensive and limited resources, to mention but
a few. However, it is my sense that our collective moral fiber in
cardiology is maturing rapidly and gaining appropriate
strength; witness the 29th Bethesda Conference on Ethics in
Cardiovascular Medicine to be published in the April 1998
issue of the Journal.
In outlining the development of interventional cardiology,
King has given us far more than an interesting history of
angioplasty. It is a marvelously succinct, richly referenced
status report on percutaneous endovascular revascularization.
After reading it, a clinician can feel almost fully briefed on this
extraordinarily extensive subject. However, it leaves you with
many more questions to ask than quibbles to be resolved. I
would only venture to add one more item to his list of “the
three most important events to occur in the field of angioplasty
(1—the development of the balloon catheter; 2—the develop-
ment of steerable guidance systems; and 3—coronary stent-
ing)” and add as the fourth: the approval of a Certificate of
Added Qualification (CAQ) in Interventional Cardiology by
the American Board of Internal Medicine (ABIM) and sanc-
tioned by the American Board of Medical Specialities
(ABMS). As King points out, this development recognizes the
exploding knowledge base underlying the discipline of inter-
ventional cardiology and its contributions to and interactions
with the field of vascular biology. It is clear that a specific body
of new knowledge has emerged beyond the mechanical “know-
how” and extends from new molecular techniques to identify,
sequence and target certain genes to in situ hybridization of
human tissue to the potential roles of reactive oxygen species
in the pathogenesis of restenosis or brachytherapy to its cure.
All this obviously requires additional training for physicians
who would be practitioners and consultants in interventional
cardiology. King himself led the movement to secure this
CAQ, and I think that it is destined to remodel the face of
Table 1. Long-Term Risk Factors of Patients Undergoing Coronary
Artery Bypass Graft Surgery Versus Percutaneous Transluminal
Coronary Angioplasty*† (New York State database 1993 to 1995,
59,576 patients)
Variable
CABG
(n 5 29,646)
PTCA
(n 5 29,930)
Stroke 5.3% 2.0%
PVD 26.7% 9.6%
Hemo-unstable 2.8% 0.8%
COPD 15.1% 4.3%
CHF 10.5% 3.6%
Diabetes 27.3% 17.4%
*p , 0.001 for all comparisons. †Data from Hannan E (personal communi-
cation, January 1998). Data presented are percent of patients. CABG 5
coronary artery bypass graft surgery; CHF 5 congestive heart failure; COPD 5
chronic obstructive pulmonary disease; Hemo-unstable 5 hemodynamically
unstable blood pressure ,90 mm Hg; PTCA 5 percutaneous transluminal
coronary angioplasty; PVD 5 peripheral vascular disease.
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interventional cardiology. It is time to shed some of the
pioneer spirit characterized by rugged individualism that was
so instrumental in bringing a young subspecialty to full bloom.
In its place there is room for more science and the develop-
ment of appropriate standards of practice based on evidence-
based medicine.
In my view, the future for interventional cardiology is more
exciting and brighter than it ever was in the dawning years of
the 1980s. It is difficult to imagine exactly what can issue from
the marriage between interventional cardiology and biomolec-
ular science, but it very likely will eclipse the happenings of the
past 30 years, which my generation likes to call “the golden age
of cardiology.”
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